Your browser doesn't support javascript.
loading
Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study.
Walhelm, Tomas; Gunnarsson, Iva; Heijke, Rebecca; Leonard, Dag; Trysberg, Estelle; Eriksson, Per; Sjöwall, Christopher.
Afiliación
  • Walhelm T; Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.
  • Gunnarsson I; Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Heijke R; Department of Internal Medicine, Jönköping, Sweden.
  • Leonard D; Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Trysberg E; Department of Rheumatology and Inflammation Research, University of Gothenburg, Göteborg, Sweden.
  • Eriksson P; Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.
  • Sjöwall C; Department of Internal Medicine, Jönköping, Sweden.
Front Immunol ; 12: 756941, 2021.
Article en En | MEDLINE | ID: mdl-34659263
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Inhibidores de Proteasoma / Bortezomib / Lupus Eritematoso Sistémico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Inhibidores de Proteasoma / Bortezomib / Lupus Eritematoso Sistémico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Suecia